203 related articles for article (PubMed ID: 34708255)
1. Low-dose LSD and the stream of thought: Increased Discontinuity of Mind, Deep Thoughts and abstract flow.
Wießner I; Falchi M; Palhano-Fontes F; Oliveira Maia L; Feilding A; Ribeiro S; Bezerra Mota N; Araujo DB; Tófoli LF
Psychopharmacology (Berl); 2022 Jun; 239(6):1721-1733. PubMed ID: 34708255
[TBL] [Abstract][Full Text] [Related]
2. LSD and language: Decreased structural connectivity, increased semantic similarity, changed vocabulary in healthy individuals.
Wießner I; Falchi M; Daldegan-Bueno D; Palhano-Fontes F; Olivieri R; Feilding A; B Araujo D; Ribeiro S; Bezerra Mota N; Tófoli LF
Eur Neuropsychopharmacol; 2023 Mar; 68():89-104. PubMed ID: 36669231
[TBL] [Abstract][Full Text] [Related]
3. LSD and creativity: Increased novelty and symbolic thinking, decreased utility and convergent thinking.
Wießner I; Falchi M; Maia LO; Daldegan-Bueno D; Palhano-Fontes F; Mason NL; Ramaekers JG; Gross ME; Schooler JW; Feilding A; Ribeiro S; Araujo DB; Tófoli LF
J Psychopharmacol; 2022 Mar; 36(3):348-359. PubMed ID: 35105186
[TBL] [Abstract][Full Text] [Related]
4. LSD, afterglow and hangover: Increased episodic memory and verbal fluency, decreased cognitive flexibility.
Wießner I; Olivieri R; Falchi M; Palhano-Fontes F; Oliveira Maia L; Feilding A; B Araujo D; Ribeiro S; Tófoli LF
Eur Neuropsychopharmacol; 2022 May; 58():7-19. PubMed ID: 35158230
[TBL] [Abstract][Full Text] [Related]
5. Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers.
Family N; Maillet EL; Williams LTJ; Krediet E; Carhart-Harris RL; Williams TM; Nichols CD; Goble DJ; Raz S
Psychopharmacology (Berl); 2020 Mar; 237(3):841-853. PubMed ID: 31853557
[TBL] [Abstract][Full Text] [Related]
6. Acute Effects of Lysergic Acid Diethylamide on Circulating Steroid Levels in Healthy Subjects.
Strajhar P; Schmid Y; Liakoni E; Dolder PC; Rentsch KM; Kratschmar DV; Odermatt A; Liechti ME
J Neuroendocrinol; 2016 Mar; 28(3):12374. PubMed ID: 26849997
[TBL] [Abstract][Full Text] [Related]
7. Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor.
Preller KH; Burt JB; Ji JL; Schleifer CH; Adkinson BD; Stämpfli P; Seifritz E; Repovs G; Krystal JH; Murray JD; Vollenweider FX; Anticevic A
Elife; 2018 Oct; 7():. PubMed ID: 30355445
[TBL] [Abstract][Full Text] [Related]
8. Role of the 5-HT
Preller KH; Schilbach L; Pokorny T; Flemming J; Seifritz E; Vollenweider FX
J Neurosci; 2018 Apr; 38(14):3603-3611. PubMed ID: 29555857
[TBL] [Abstract][Full Text] [Related]
9. Acute Subjective and Behavioral Effects of Microdoses of Lysergic Acid Diethylamide in Healthy Human Volunteers.
Bershad AK; Schepers ST; Bremmer MP; Lee R; de Wit H
Biol Psychiatry; 2019 Nov; 86(10):792-800. PubMed ID: 31331617
[TBL] [Abstract][Full Text] [Related]
10. LSD, madness and healing: Mystical experiences as possible link between psychosis model and therapy model.
Wießner I; Falchi M; Palhano-Fontes F; Feilding A; Ribeiro S; Tófoli LF
Psychol Med; 2023 Mar; 53(4):1151-1165. PubMed ID: 34253268
[TBL] [Abstract][Full Text] [Related]
11. Repeated low doses of LSD in healthy adults: A placebo-controlled, dose-response study.
de Wit H; Molla HM; Bershad A; Bremmer M; Lee R
Addict Biol; 2022 Mar; 27(2):e13143. PubMed ID: 35106880
[TBL] [Abstract][Full Text] [Related]
12. Ketanserin Reverses the Acute Response to LSD in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Participants.
Becker AM; Klaiber A; Holze F; Istampoulouoglou I; Duthaler U; Varghese N; Eckert A; Liechti ME
Int J Neuropsychopharmacol; 2023 Feb; 26(2):97-106. PubMed ID: 36342343
[TBL] [Abstract][Full Text] [Related]
13. Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects.
Holze F; Ley L; Müller F; Becker AM; Straumann I; Vizeli P; Kuehne SS; Roder MA; Duthaler U; Kolaczynska KE; Varghese N; Eckert A; Liechti ME
Neuropsychopharmacology; 2022 May; 47(6):1180-1187. PubMed ID: 35217796
[TBL] [Abstract][Full Text] [Related]
14. The paradoxical psychological effects of lysergic acid diethylamide (LSD).
Carhart-Harris RL; Kaelen M; Bolstridge M; Williams TM; Williams LT; Underwood R; Feilding A; Nutt DJ
Psychol Med; 2016 May; 46(7):1379-90. PubMed ID: 26847689
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide Microdoses in Healthy Participants.
Holze F; Liechti ME; Hutten NRPW; Mason NL; Dolder PC; Theunissen EL; Duthaler U; Feilding A; Ramaekers JG; Kuypers KPC
Clin Pharmacol Ther; 2021 Mar; 109(3):658-666. PubMed ID: 32975835
[TBL] [Abstract][Full Text] [Related]
16. Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study.
Hutten NRPW; Mason NL; Dolder PC; Theunissen EL; Holze F; Liechti ME; Feilding A; Ramaekers JG; Kuypers KPC
Eur Neuropsychopharmacol; 2020 Dec; 41():81-91. PubMed ID: 33082016
[TBL] [Abstract][Full Text] [Related]
17. Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects.
Holze F; Vizeli P; Ley L; Müller F; Dolder P; Stocker M; Duthaler U; Varghese N; Eckert A; Borgwardt S; Liechti ME
Neuropsychopharmacology; 2021 Feb; 46(3):537-544. PubMed ID: 33059356
[TBL] [Abstract][Full Text] [Related]
18. Characterizing Thalamocortical (Dys)connectivity Following D-Amphetamine, LSD, and MDMA Administration.
Avram M; Müller F; Rogg H; Korda A; Andreou C; Holze F; Vizeli P; Ley L; Liechti ME; Borgwardt S
Biol Psychiatry Cogn Neurosci Neuroimaging; 2022 Sep; 7(9):885-894. PubMed ID: 35500840
[TBL] [Abstract][Full Text] [Related]
19. Greater subjective effects of a low dose of LSD in participants with depressed mood.
Molla H; Lee R; Tare I; de Wit H
Neuropsychopharmacology; 2024 Apr; 49(5):774-781. PubMed ID: 38042914
[TBL] [Abstract][Full Text] [Related]
20. LSD modulates music-induced imagery via changes in parahippocampal connectivity.
Kaelen M; Roseman L; Kahan J; Santos-Ribeiro A; Orban C; Lorenz R; Barrett FS; Bolstridge M; Williams T; Williams L; Wall MB; Feilding A; Muthukumaraswamy S; Nutt DJ; Carhart-Harris R
Eur Neuropsychopharmacol; 2016 Jul; 26(7):1099-109. PubMed ID: 27084302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
